Divergent effects of oxytocin treatment of obese diabetic mice on adiposity and diabetes

Endocrinology (United States)

Volumn 155, Issue 11, 2014, Pages 4189-4201

  Altirriba, Jordi ^a   Poher, Anne Laure ^a   Caillon, Aurélie ^a   Arsenijevic, Denis ^b   Veyrat Durebex, Christelle ^a   Lyautey, Jacqueline ^a   Dulloo, Abdul ^b   Rohner Jeanrenaud, Franҫoise ^a  

^a UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

^b UNIVERSITY OF FRIBOURG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

(THREONINE 4,GLYCINE 7)OXYTOCIN; CARBETOCIN; CORTICOSTERONE; FATTY ACID SYNTHASE; GLUCOSE; HORMONE; INSULIN; OXYTOCIN; OXYTOCIN DERIVATIVE; OXYTOCIN RECEPTOR; PYRUVIC ACID; UNCLASSIFIED DRUG;

ABDOMINAL FAT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY COMPOSITION; BODY WEIGHT; CONTROLLED STUDY; DIABETES MELLITUS; DOSE RESPONSE; DRUG EFFECT; DRUG HALF LIFE; ENZYME ACTIVITY; FAT MASS; FLUID INTAKE; FOOD INTAKE; GENE EXPRESSION; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; HYPERINSULINEMIA; INFLAMMATION; INSULIN TOLERANCE TEST; LIPID TRANSPORT; LIPOGENESIS; MALE; METABOLIC PARAMETERS; MOUSE; NONHUMAN; OBESITY; PYRUVATE TOLERANCE; WEIGHT GAIN; WEIGHT REDUCTION; ADIPOSE TISSUE; ANIMAL; C57BL MOUSE; COMPLICATION; DIABETES MELLITUS, EXPERIMENTAL; DRUG EFFECTS; LIVER; METABOLISM; MOUSE MUTANT; PATHOLOGY;

ADIPOSE TISSUE; ADIPOSITY; ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUCOSE; LIVER; MALE; MICE; MICE, INBRED C57BL; MICE, OBESE; OBESITY; OXYTOCIN; THINNESS;

EID: 84908046867     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2014-1466     Document Type: Article

References (43)

1. World Health Organization. Global Health Risks: Mortality and Burden of Disease Attributable to Selected Major Risks. Geneva, Switzerland; 2009. http://www.who.int/healthinfo/global-burden-disease/GlobalHealthRisks-report-full.pdf.
2. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2014;37(suppl 1):S81-S90.
3. Meyer-Lindenberg A, Domes G, Kirsch P, Heinrichs M. Oxytocin and vasopressin in the human brain: social neuropeptides for translational medicine. Nat Rev Neurosci. 2011;12(9):524-538.
4. Gimpl G, Fahrenholz F. The oxytocin receptor system: structure, function, and regulation. Physiol Rev. 2001;81(2):629-683.
5. Kenyon S, Tokumasu H, Dowswell T, Pledge D, Mori R. High-dose versus low-dose oxytocin for augmentation of delayed labour. Cochrane Database Syst Rev. 2013;7:CD007201.
6. Gizzo S, Patrelli TS, Gangi SD, et al. Which uterotonic is better to prevent the postpartum hemorrhage? Latest news in terms of clinical efficacy, side effects, and contraindications: a systematic review. Reprod Sci. 2013;20(9):1011-1019.
7. Bakermans-Kranenburg MJ. van IJMH. Sniffing around oxytocin: review and meta-analyses of trials in healthy and clinical groups with implications for pharmacotherapy. Transl Psychiatry. 2013;3:e258.
8. Zhang H, Wu C, Chen Q, et al. Treatment of obesity and diabetes using oxytocin or analogs in patients and mouse models. PLoS One. 2013;8(5):e61477.
9. Deblon N, Veyrat-Durebex C, Bourgoin L, et al. Mechanisms of the anti-obesity effects of oxytocin in diet-induced obese rats. PLoS One. 2011;6(9):e25565.
10. Zhang G, Bai H, Zhang H, et al. Neuropeptide exocytosis involving synaptotagmin-4 and oxytocin in hypothalamic programming of body weight and energy balance. Neuron. 2011;69(3):523-535.
11. Morton GJ, Thatcher BS, Reidelberger RD, et al. Peripheral oxytocin suppresses food intake and causes weight loss in diet-induced obese rats. Am J Physiol Endocrinol Metab. 2012;302(1):E134-E144.
12. Maejima Y, Iwasaki Y, Yamahara Y, Kodaira M, Sedbazar U, Yada T. Peripheral oxytocin treatment ameliorates obesity by reducing food intake and visceral fat mass. Aging (Albany NY). 2011;3(12):1169-1177.
13. Maejima Y, Sedbazar U, Suyama S, et al. Nesfatin-1-regulated oxytocinergic signaling in the paraventricular nucleus causes anorexia through a leptin-independent melanocortin pathway. Cell Metab. 2009;10(5):355-365.
14. Ott V, Finlayson G, Lehnert H, et al. Oxytocin reduces reward-driven food intake in humans. Diabetes. 2013;62(10):3418-3425.
15. Penicaud L, Ferre P, Assimacopoulos-Jeannet F, et al. Increased gene expression of lipogenic enzymes and glucose transporter in white adipose tissue of suckling and weaned obese Zucker rats. Biochem J. 1991;279(pt 1):303-308.
16. Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nat Methods. 2012;9(7):671-675.
17. R Core Team R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2013. http://www.R-project.org.
18. Cort N, Einarsson S, Schams D, Vilhardt H. Blood concentrations of oxytocin equivalents after single injections of deamino-1-mono-carba-[2-O-methyltyrosine]-oxytocin in lactating sows. Am J Vet Res. 1981;42(10):1804-1806.
19. Busnelli M, Bulgheroni E, Manning M, Kleinau G, Chini B. Selective and potent agonists and antagonists for investigating the role of mouse oxytocin receptors. J Pharmacol Exp Ther. 2013;346(2):318-327.
20. Ariño J, Bosch F, Gómez-Foix AM, Guinovart JJ. Oxytocin inactivates and phosphorylates rat hepatocyte glycogen synthase. Biochem J. 1989;261(3):827-830.
21. Hunter DJ, Schulz P, Wassenaar W. Effect of carbetocin, a long-acting oxytocin analog on the postpartum uterus. Clin Pharmacol Ther. 1992;52(1):60-67.
22. Langhans W, Delprete E, Scharrer E. Mechanisms of vasopressin's anorectic effect. Physiol Behav. 1991;49(1):169-176.
23. Arletti R, Benelli A, Bertolini A. Influence of oxytocin on feeding behavior in the rat. Peptides. 1989;10(1):89-93.
24. Arletti R, Benelli A, Bertolini A. Oxytocin inhibits food and fluid intake in rats. Physiol Behav. 1990;48(6):825-830.
25. Boland D, Goren HJ. Binding and structural properties of oxytocin receptors in isolated rat epididymal adipocytes. Regul Pept. 1987;18(1):7-18.
26. Wu C, Orozco C, Boyer J, et al. BioGPS: an extensible and customizable portal for querying and organizing gene annotation resources. Genome Biol. 2009;10(11):R130.
27. Goren HJ, Hanif K, Dudley R, Hollenberg MD, Lederis K. Adenosine modulation of fat cell responsiveness to insulin and oxytocin. Regul Pept. 1986;16(2):125-134.
28. Eriksson H, Björgell P, Akerlund M, Hauksson A, Melin P. Effects of a tocolytic oxytocin analogue on lipid and carbohydrate metabolism. Gynecol Obstet Invest. 1990;29(2):97-100.
29. Muchmore DB, Little SA, de Haën C. A dual mechanism of action of ocytocin in rat epididymal fat cells. J Biol Chem. 1981;256(1):365-372.
30. Perello M, Raingo J. Leptin activates oxytocin neurons of the hypothalamic paraventricular nucleus in both control and diet-induced obese rodents. PLoS One. 2013;8(3):e59625.
31. Blevins JE, Schwartz MW, Baskin DG. Evidence that paraventricular nucleus oxytocin neurons link hypothalamic leptin action to caudal brain stem nuclei controlling meal size. Am J Physiol Regul Integr Comp Physiol. 2004;287(1):R87-R96.
32. Buettner C, Muse ED, Cheng A, et al. Leptin controls adipose tissue lipogenesis via central, STAT3-independent mechanisms. Nat Med. 2008;14(6):667-675.
33. Zhang G, Cai D. Circadian intervention of obesity development via resting-stage feeding manipulation or oxytocin treatment. Am J Physiol Endocrinol Metab. 2011;301(5):E1004-E1012.
34. Rashed LA, Hashem RM, Soliman HM. Oxytocin inhibits NADPH oxidase and P38 MAPK in cisplatin-induced nephrotoxicity. Biomed Pharmacother. 2011;65(7):474-480.
35. Szkudelski T. The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas. Physiol Res. 2001;50(6):537-546.
36. Gao ZY, Drews G, Henquin JC. Mechanisms of the stimulation of insulin release by oxytocin in normal mouse islets. Biochem J. 1991;276(pt 1):169-174.
37. Pivonello R, De Leo M, Vitale P, et al. Pathophysiology of diabetes mellitus in Cushing's syndrome. Neuroendocrinology. 2010;92(suppl 1):77-81.
38. Kusui C, Kimura T, Ogita K, et al. DNA methylation of the human oxytocin receptor gene promoter regulates tissue-specific gene suppression. Biochem Biophys Res Commun. 2001;289(3):681-686.
39. Whitton PD, Rodrigues LM, Hems DA. Stimulation by vasopressin, angiotensin and oxytocin of gluconeogenesis in hepatocyte suspensions. Biochem J. 1978;176(3):893-898.
40. Katz N, Brinkmann A, Jungermann K. Compensatory increase of the gluconeogenic capacity of rat kidney after partial hepatectomy. Hoppe Seylers Z Physiol Chem. 1979;360(1):51-57.
41. Habold C, Foltzer-Jourdainne C, Le Maho Y, Lignot JH, Oudart H. Intestinal gluconeogenesis and glucose transport according to body fuel availability in rats. J Physiol. 2005;566(pt 2):575-586.
42. Cherrington AD, Chiasson JL, Liljenquist JE, Lacy WW, Park CR. Control of hepatic glucose output by glucagon and insulin in the intact dog. Biochem Soc Symp. 1978(43):31-45.
43. Perry RJ, Zhang XM, Zhang D, et al. Leptin reverses diabetes by suppression of the hypothalamic-pituitary-adrenal axis. Nat Med. 2014;20(7):759-763.